Efficacy and safety of biologics in erythrodermic psoriasis: A multicentre, retrospective study

British Journal of Dermatology

Volumn 167, Issue 2, 2012, Pages 417-423

  Viguier, M ^a   Pages C ^a   Aubin, F ^b   Delaporte, E ^c   Descamps, V ^d   Lok, C ^e   Beylot Barry, M ^f   Seneschal J ^f   Dubertret, L ^a   Morand, J J ^g   Dreno B ^h   Bachelez, H ^a  

^a Paris Diderot Sorbonne Cite University   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c UNIV LILLE   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

^g LAVERAN MILITARY TEACHING HOSPITAL   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PSORALEN; USTEKINUMAB;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL INFECTION; BODY SURFACE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYSIPELAS; ERYTHRODERMIC PSORIASIS; FEMALE; FURUNCULOSIS; HEART INFARCTION; HUMAN; IMMUNOALLERGIC SHOCK; LYMPHOMA; MALE; MULTICENTER STUDY; PHOTOTHERAPY; PNEUMONIA; PRIORITY JOURNAL; PSORIASIS AREA AND SEVERITY INDEX; QUALITY OF LIFE; RATING SCALE; RETROSPECTIVE STUDY; SEPTIC SHOCK; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; SUDDEN DEATH; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET A RADIATION; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOLOGICAL AGENTS; CHILD; CHILD, PRESCHOOL; DERMATITIS, EXFOLIATIVE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864399641     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10940.x     Document Type: Article

References (35)

1. Griffiths CE, Christophers E, Barker JN, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 156: 258-62.
2. Boyd AS, Menter A,. Erythrodermic psoriasis. Precipitating factors, course, and prognosis in 50 patients. J Am Acad Dermatol 1989; 21: 985-91.
3. Jalal O, Houass S, Laissaoui K, et al. Formes graves de psoriasis: 160 cas. Ann Dermatol Venereol 2005; 132: 126-8.
4. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-74.
5. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-22.
6. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
7. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
8. Griffiths CE, Strober BE, Van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
9. Schmitt J, Zhang Z, Wozel G, et al. Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials. Br J Dermatol 2008; 159: 513-26.
10. Langley RG, Strober BE, Gu Y, et al. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. Br J Dermatol 2010; 162: 1349-58.
11. O'Quinn RP, Miller JL,. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol 2002; 138: 644-8.
12. Rongioletti F, Borenstein M, Kirsner R, Kerdel F,. Erythrodermic, recalcitrant psoriasis: clinical resolution with infliximab. J Dermatolog Treat 2003; 14: 222-5.
13. Heikkilä H, Ranki A, Cajanus S, Karvonen SL,. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol 2005; 141: 1607-10.
14. Poulalhon N, Begon E, Lebbé C, et al. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity. Br J Dermatol 2007; 156: 329-36.
15. Takahashi MD, Castro LG, Romiti R,. Infliximab, as sole or combined therapy, induces rapid clearing of erythrodermic psoriasis. Br J Dermatol 2007; 157: 828-31.
16. Piccirillo F, Stinco G, Patrone P,. Erythrodermic psoriasis successfully treated with efalizumab. Eur J Dermatol 2008; 18: 357-8.
17. Yip L, Harrison S, Foley P,. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis. Australas J Dermatol 2008; 49: 152-5.
18. Santos-Juanes J, Coto-Segura P, Mas-Vidal A, Galache Osuna C,. Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies. Br J Dermatol 2010; 162: 1144-6.
19. Romero-Maté A, García-Donoso C, Martinez-Morán C, et al. Long-term management of erythrodermic psoriasis with anti-TNF agents. Dermatol Online J 2010; 16: 15.
20. Esposito M, Mazzotta A, De Felice C, et al. Treatment of erythrodermic psoriasis with etanercept. Br J Dermatol 2006; 155: 156-9.
21. Green MS, Prystowsky JH, Cohen SR, et al. Infectious complications of erythrodermic psoriasis. J Am Acad Dermatol 1996; 34: 911-14.
22. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 2368-76.
23. Marks J,. Erythrodermas and uric acid aberrations in psoriasis. In: Psoriasis: Proceedings of the International Symposium (, Farber EM, Cox AJ, eds), Stanford, CA: Stanford University Press, 1971; 89-98.
24. Goeckerman WH, O'Leary PA,. Erythroderma psoriaticum: a review of 22 cases. JAMA 1932; 99: 2102-5.
25. Roth PE, Grosshans E, Bergoend H,. Psoriasis: évolution et complications mortelles. Ann Dermatol Venereol 1991; 118: 97-105.
26. Wang TS, Tsai TF,. Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: a case series. J Dermatol 2011; 38: 1-4.
27. Richetta AG, Maiani E, Carlomagno V, et al. Treatment of erythrodermic psoriasis in HCV+ patient with adalimumab. Dermatol Ther 2009; 22: S16-18.
28. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
29. Pathirana D, Nast A, Ormerod AD, et al. On the development of the European S3 guidelines on the systemic treatment of psoriasis vulgaris: structure and challenges. J Eur Acad Dermatol Venereol 2010; 24: 1458-67.
30. Rosenbach M, Hsu S, Korman NJ, et al. National Psoriasis Foundation Medical Board. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2010; 62: 655-62.
31. Gniadecki R, Kragballe K, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-6.
32. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the 3-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 6: 1884-94.
33. Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70: 616-23.
34. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010; 69: 522-8.
35. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306: 864-71.